32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00346281|
Recruitment Status : Unknown
Verified June 2006 by pSiMedica Limited.
Recruitment status was: Recruiting
First Posted : June 29, 2006
Last Update Posted : June 29, 2006
This is the first study investigating the safety of 32P BioSilicon in patients with advanced,unresectable pancreatic cancer who are also receiving standard intravenous gemcitabine chemotherapy. The secondary aims of the study will assess the implantation procedure, localisation of 32P BioSilicon, tumour response and survival parameters.
Tumours targetted with 32P BioSilicon is hypothesized to show a reduction in tumour volume and with the low radioactivity dose that is delivered intratumourally, the incidence of side effects associated with the treatment is expected to be low. Prologation of survival and improved quality of life could be favourable outcomes of the investigational product.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Device: 32P BioSilicon||Phase 2|
This will be an open label, Phase IIa safety study recruiting about 15 patients from at least two sites. All patients will have 32P BioSilicon implanted into the pancreatic tumour as a single implant, using endoscopic ultrasound. The study will examine the safety of an injected activity equivalent to an absorbed dose of 100 Gy (which is considered to be an initial low risk radioactivity level), administered intratumourally to patients with pancreatic cancer. All patients will receive gemcitabine treatment within 2 weeks prior to or within 3 days of implantation. Any dose adjustments to the gemcitabine treatment will be made according to the clinical judgement of the oncologist in the team and this will be made in accordance with the current approved prescribing receommendations. Implantation of 32P BioSilicon will be performed endoscopically by a trained endoscopist and a nuclear medicine physician. The 32P BioSilicon will be prepared by a designated personnel licenced to handle radioactive products and all radioactive waste will be handled and managed as per the institution's guidelines and in compliance with local regulatory requirements. Bremsstrahlung imaging will be performed post implantation as a preliminary indication of localisation of the implanted 32P BioSiliconTM.
Assessments will be performed for haematology, biochemistry, CA19-9 marker, performance status and any adverse event observed or reported will be graded according to the CTCAE. To minimise inter-observer variation, the patient should be assessed by the same investigator throughout the study. Tumour assessment and tumour volume calculation will be performed by designated radiologists who are independent of the study. To standardise, the CT scans will be performed according to an agreed scanning protocol and the images will be captured in a DICOM format at site for assessment by the independent radiologist. Tumour response will be evaluated only for target tumours using RECIST.
Pain assessment using the Brief Pain Inventory (BPI) pain score will be recorded by the patient.
Patients who have clinically and/or radiologically stable or responding disease have the option to continue gemcitabine, at the discretion of the investigator. Following discontinuation from the study, patients will be followed up for progression-free, and overall survival.
A Data Monitoring Committee will review the study data at regular teleconference throughout the study.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IIa, Safety Study of the Active Implantable(Radiological) Medical Device 32P BioSilicon, Administered Intratumourally to Patients With Advanced, Unresectable Pancreatic Cancer, in Addition to Standard IV Gemcitabine Chemotherapy|
|Study Start Date :||June 2006|
|Study Completion Date :||June 2008|
- Safety profile of the patients defined by the Adverse Events profile.
- Will assess ease of use, tumour response, duration of response, progression free survival and overall survival. Target tumour response summaries for the study will be performed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00346281
|Singapore General Hospital||Recruiting|
|Outram Road, Singapore, 169608|
|Contact: Pierce KH Chow, MBBS,PhD +65 6326 6091 email@example.com|
|Contact: K F Foo, MBBS, MMed +65 6436 8445 firstname.lastname@example.org|
|Principal Investigator: Pierce KH Chow, MBBS,PhD|
|Sub-Investigator: K F Foo, MBBS, MMed|
|Sub-Investigator: Steven Mesenas, MBBS, MRCP|
|Sub-Investigator: Anthony SW Goh, MBBS, MSc|
|Sub-Investigator: W K Wong, MBBS|
|Sub-Investigator: Alexander YF Chung, MBBS|
|Sub-Investigator: P C Cheow, MBBS, MMed|
|Sub-Investigator: David CE Ng, MBBS, MSc|
|Sub-Investigator: S. Somanesan, BSc (Hons)|
|Sub-Investigator: K M Hoi, BSc (Hons)|
|Guy's and St Thomas' Hospital NHS Trust||Recruiting|
|London, United Kingdom, SE1 9RT|
|Contact: Paul Ross, MBBS,PhD 020 7188 4249 email@example.com|
|Principal Investigator: Paul Ross, MBBS, PhD|
|Sub-Investigator: David Landau, MBBS, MRCP|
|Sub-Investigator: Peter Harper, MBBS, MRCP|
|Sub-Investigator: John Meenan, MBBS, PhD|
|Sub-Investigator: Mike O'Doherty, MBBS, MD|
|Sub-Investigator: Jim Ballinger, PhD|
|Sub-Investigator: Stanley Batchelor, MSc|
|Principal Investigator:||Pierce KH Chow, MBBS, PhD||Singapore General Hospital|
|Principal Investigator:||Paul Ross, MBBS,PhD||Guy's and St Thomas' NHS Foundation Trust|